Market research
3750.TSE FRACTALE Corporation
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.16
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3426500009
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.16
About
About FRACTALE Corporation
ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, meniscus repair, stress urinary incontinence scleroderma, vocal cord repair, liver cirrhosis, and other diseases. In addition, it provides real estate services. The company was formerly known as ADR120S, Inc. and changed its name to ADR Biomedical Holdings Inc. in July 2026. ADR Biomedical Holdings Inc. was incorporated in 2004 and is headquartered in Chiyoda, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 3750.TSE discussion.
5 years, 6 months ago
FRACTALE Corporation is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.
From a valuation standpoint, the stock is 67.5% more expensive than other stocks from the Real Estate sector with a price to sales ratio of 8.1.
FRACTALE Corporation's total revenue sank by 24.8% to $364M since the same quarter in the previous year.
Its net income has increased by 23.5% to $-42M since the same quarter in the previous year.
Based on the above factors, FRACTALE Corporation gets an overall score of 1/5.